Tycel J. Phillips, MD, on Marginal Zone Lymphoma: Efficacy and Safety of Parsaclisib

January 05, 2021 By The ASCO Post Staff

Tycel J. Phillips, MD, of the University of Michigan Rogel Cancer Center, discusses phase II data from the CITADEL-204 study, showing that patients with relapsed or refractory marginal zone lymphoma who were not previously treated with a Bruton’s tyrosine kinase inhibitor achieved rapid and durable responses with single-agent parsaclisib. Comparable results were also observed in patients with nodal, extranodal, or splenic disease (Abstract 338).

Related Content